NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.58 +0.59 (+0.75%) GOLD FUTURES
2,348.20 +25.90 (+1.12%) DOW
39,386.93 +330.54 (+0.85%) Bitcoin GBP
49,746.02 +3.71 (+0.01%)
Perspective Therapeutics, Inc. (CATX)
| Previous close | 1.7600 |
| Open | 1.8000 |
| Bid | 1.7800 x 3100 |
| Ask | 1.7900 x 4000 |
| Day's range | 1.7300 - 1.8250 |
| 52-week range | 0.2100 - 1.9000 |
| Volume | |
| Avg. volume | 4,394,695 |
| Market cap | 1.054B |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals D
- GlobeNewswire
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/pre
- GlobeNewswire
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in the Chemistry, Manufacturing, and Controls (“CMC”) Development and Readin
